Please sign in to follow a disease.
New scanner aims to cut cancer scans in half
NCT ID NCT05844306
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a new PET-CT scanner built into the RefleXion radiotherapy system with standard PET-CT scans in 20 adults with various cancers. The goal is to see if the new scanner can find the same cancer spots, so patients might need fewer scans before radiation therapy. The study is currently suspended.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2023
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Age: \>= 21 years * Patients with malignancies (abdominal/pelvic/thoracic/head and neck/breast tumors) undergoing SOC \[18F\]-FDG PET-CT for diagnostic and/or radiotherapy planning purposes * Patients should be scheduled for \[18F\]-FDG PET-CT prior to study entry Exclusion Criteria: * Known psychiatric or substance abuse disorder that would interfere with conduct of the study * Patient weight exceeding the weight limit (450 pounds) outlined per X1 RMRS specifications sheet * Lung parenchymal and bone tumors will be excluded as their imaging characteristics were evaluated in a previous study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hematopoietic and lymphoid system neoplasm are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a vaccine stop GI cancers from returning?
- Can a phone app help childhood cancer survivors keep track of their health?
- Can the way we word cancer research invitations boost participation?
- A chill pill for Chemo's side effects? cooling therapy and a Blood-Flow drug take on nerve pain
- Wearable tech could spot Post-Surgery problems early
- Can an AI chatbot ease the aftermath of cancer?